List view / Grid view
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several…
The new organoids demonstrate a greater diversity of TECs in culture and are capable of maturing T cells.
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
Epigenetic data assessing the effects of smoking on DNA methylation could serve as biomarkers of exposure effects.
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
